The punishment of every disordered mind is its own disorder.”― St. Augustine of Hippo, Confessions
It looks like trade tensions will continue to be front and center this week after they caused a spike of volatility in the markets last week. Futures are slightly down as we get set to start a new trading week.
While we await the opening bell, here are four biotech stocks garnering some analyst praise this morning.
We advise buying the dip as our investment thesis hasn’t changed: Evolus has a high-quality cosmetic toxin in a rapidly growing market that is backed by a seasoned, innovative management team. The company already signed up 2,100 clinics as customers, assuring rapid uptake. We believe that the “unveiling” of the patient loyalty program later in the year will serve as a key catalyst for the stock.”
Iovance Biotherapeutics (IOVA) keeps picking up analyst 'shout outs'. Today it is Chardan Capital reissuing its Buy rating and $30 price target. Late last week H.C. Wainwright ($26 price target), Robert W. Baird ($34 price target), B Riley FBR ($24 price target) and Jefferies ($29 price target) all reiterated their own Buy ratings on this small cap concern. We just posted an investment update on this name as well.
Do you have a good handle on simple option strategies that can boost your portfolio returns?. '10 Simple Rules To Trade Options Like A Pro' from our friends at Investors Alley is a good quick overview on using option strategies to mitigate risk and enhance returns in your portfolio. These strategies are well suited to high beta sectors like biotech where option premiums tend to be large. The report is now available free via download HERE
Next up is Myokardia (MYOK). JP Morgan maintains its Overweight rating but lifts is price target a sawbuck to $85 a share. Morgan's analyst cites 'the potential of the company's lead asset mavacamten for the treatment of hypertrophic cardiomyopathy. There is a significant unmet need in hypertrophic cardiomyopathy and need for new treatment options. His work suggests that physicians view the totality of PIONEER-HCM data as "very encouraging / impressive." The analyst estimates mavacamten has $2.5B-plus sales potential in the U.S. alone'Finally, The Medicines Group (MDCO) posted encouraging trial data today. B Riley FBR is the first to reissue their Buy rating and $38 price target this morning. Here is their view on the trial results.
The company announced interim results from the ongoing ORION-3 Ph. II open-label long-term extension study which were also presented during a late-breaking clinical trial session at the National Lipid Association (NLA) Scientific Session in Miami. These interim data was reported from Group 1 patients (n=290) who were previously treated with either of the two inclisiran dose regimens in ORION-1 Ph. II double blind trial for ~ 1 year and subsequently received twice-a-year injections of inclisiran 300 mg as part of ORION-3 protocol inclusive of primary endpoint reported at ~22 months of treatment.”
And those are four small cap concerns analysts are singling out today.
Our anxiety does not come from thinking about the future, but from wanting to control it.” ― Kahlil Gibran
We are about to publish an extensive in-depth look at Biogen (BIIB) and how we would play the recent decline in the stock. If you are signed up to receive our free reports, that should be in your 'in' box within the next 48 hours. If you want this investment analysis and are not registered yet, just go to bretjenseninvests.com and hit the 'free reports' tab to download our latest report. This action will also register you for all the free reports we put out going forward as published as well.
Thank You & Happy Hunting,